Panobinostat (LBH589)

Name: Panobinostat (LBH589)
Brand: Selleck Chemicals
SKU: S1030
Rating: 5 (236 reviews)

For research use only.

Catalog No.S1030 Synonyms: NVP-LBH589

236 publications

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Panobinostat (LBH589) induces autophagy and apoptosis. Panobinostat effectively disrupts HIV latency in vivo. Phase 3.

Selleck's Panobinostat (LBH589) has been cited by 236 publications

Nat Biotechnol, 2020, 10.1038/s41587-019-0388-4

PubMed: 31959954 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 36(5):528-544

PubMed: 31631026 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):782-797

PubMed: 31085178 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nat Genet, 2018, 50(10):1442-1451

PubMed: 30224647 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 20;159(5):1110-1125.

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Nat Commun, 2020, 11(1):583

PubMed: 31996670 ( click the link to review the publication )

Genome Med, 2020, 18;12(1):17

PubMed: 32070411 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33046

PubMed: 32599665 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 9;39(1):105

PubMed: 32517809 ( click the link to review the publication )

Cancers (Basel), 2020, 5;12(6):E1478

PubMed: 32517016 ( click the link to review the publication )

PLoS Pathog, 2020, 16(3):e1008442

PubMed: 32196533 ( click the link to review the publication )

Cells, 2020, 9(2)

PubMed: 32059481 ( click the link to review the publication )

Am J Cancer Res, 2020, 10(6):1827-1843

PubMed: 32642294 ( click the link to review the publication )
Mol Cancer Res, 2020, 10.1158/1541-7786.MCR-19-0669

PubMed: 32238439 ( click the link to review the publication )

Front Oncol, 2020, 10:296

PubMed: 32195191 ( click the link to review the publication )

Sci Rep, 2020, 10(1):3470

PubMed: 32103105 ( click the link to review the publication )

Fluids Barriers CNS, 2020, 2;17(1):37

PubMed: 32487241 ( click the link to review the publication )

Exp Hematol, 2020, 81:32-41

PubMed: 31954171 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04021-y

PubMed: 31894347 ( click the link to review the publication )

Mol Cancer Ther, 2020, 19(2):637-649

PubMed: 31784455 ( click the link to review the publication )

Blood Adv, 2020, 4(5):819-829

PubMed: 32126142 ( click the link to review the publication )

Cell Res, 2019, 29(4):286-304

PubMed: 30631154 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3319

PubMed: 31346162 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz215

PubMed: 31711240 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )

Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )
Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):134

PubMed: 31801577 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

J Biomed Nanotechnol, 2019, 15(5):979-992

PubMed: 30890229 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

J Neurochem, 2019, 10.1111/jnc.14935

PubMed: 31811660 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18970-18984

PubMed: 30916359 ( click the link to review the publication )

Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

J Virol, 2019, 93(24)

PubMed: 31578289 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Epigenetics Chromatin, 2019, 12(1):18

PubMed: 30871586 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(12):2230-2240

PubMed: 31478563 ( click the link to review the publication )
Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Mol Genet Genomic Med, 2019, 7(5):e613

PubMed: 30891950 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4866

PubMed: 30451831 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Oncogene, 2018, 37(6):722-731

PubMed: 29059175 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(2):381-392

PubMed: 28839000 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

J Immunol, 2018, 201(3):1086-1096

PubMed: 29914885 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )
J Virol, 2018, 92(6)

PubMed: 29298886 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9472

PubMed: 29930256 ( click the link to review the publication )

J Proteome Res, 2018, 17(4):1436-1451

PubMed: 29564889 ( click the link to review the publication )

Biomed Pharmacother, 2018, 100:509-520

PubMed: 29494986 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

J Ethnopharmacol, 2018, 211:267-277

PubMed: 28970153 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):196-207

PubMed: 29317217 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0208147

PubMed: 30592723 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(1):61-74

PubMed: 29049036 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36530-36541

PubMed: 30559935 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28586-28598

PubMed: 29983882 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 100(1):174-187

PubMed: 29107335 ( click the link to review the publication )

Nat Commun, 2017, 8(1):728

PubMed: 28959017 ( click the link to review the publication )

Cancer Res, 2017, 77(11):3027-3039

PubMed: 28363998 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )
Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Br J Haematol, 2017, 178(5):728-738

PubMed: 28480959 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Horm Cancer, 2017, 8(4):257-267

PubMed: 28516379 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )

Oncotarget, 2017, 8(18):30019-30029

PubMed: 28415789 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56747-56757

PubMed: 28915627 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94569-94579

PubMed: 29212250 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )
Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Oncogene, 2016, 35(46):6026-6037

PubMed: 27157610 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2016, 3:16003

PubMed: 27626039 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

Sci Rep, 2016, 6:30749

PubMed: 27480951 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

J Org Chem, 2016, 81(22):11324-11334

PubMed: 27768313 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )

Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Nat Commun, 2015, 3;6:10091

PubMed: 26631872 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )
J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Antimicrob Agents Chemother, 2015, 59(7):3984-94

PubMed: 25896701 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0126566

PubMed: 26176219 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134426

PubMed: 26247786 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )

Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2088-100

PubMed: 25576920 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )
PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )
Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Targets

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. ^[1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	M3XYW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXnWeG1GOC1zMDFOwG0>	NUj6U5Q5OC12IHS=		MkDWbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NUfhTnB2OjZ5MEK3PFQ>
HepG2	M4TTbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7hPHExNTFyIN88US=>	NV;tR2h2OC12IHS=		Mn;SbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MUmyOlcxOjd6NB?=
HT29	NUH2V4VOTnWwY4Tpc44hSXO\|YYm=	MXq1NOKhdk1?	M3HPelI1NTd{IHi=		M2fjcYlv\HWlZXSgZYN1cX[jdHnvckBw\iClYYPwZZNmKDNiYX\0[ZIhPDkEoHlCpC=>	MW[yOlcxOjd6NB?=
HepG2	NUD3cHNrTnWwY4Tpc44hSXO\|YYm=	MoDmOVDDqG6P	NES1T4IzPC15MjDo		NGnkdY9qdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB\|IHHmeIVzKDJ2wrDoxsA>	NVLPVm9pOjZ5MEK3PFQ>
HCC827	NYHKcHpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mnq3OU84NjVxMUCgcm0>	M3\iVFczyqCq	MX\EUXNQ	M2m4PIVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk	MlHUNlY3PzV2OES=
A549	NYL0XIxkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIDqXXMyOC9zNT:yNEBvVQ>?	MY[3NuKhcA>?	NXfsc\|h6TE2VTx?=	M{jTVIVvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk	NUL6c5VlOjZ4N{W0PFQ>
NCI-H460	Mn3wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\HdVExNzJyL{OwJI5O	MXu3NuKhcA>?	NGPqXmZFVVOR	M3nR[4VvcGGwY3XzJJRp\SCjboTpdJJwdGmoZYLheIl3\SCnZn\lZ5Qhd2ZiZYLsc5Rqdmmk	NIPMdoYzPjZ5NUS4OC=>
J89GFP	NWXLfXhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			M4D3fGROW00EoB?=	M{Lle2VEPTB;NEmuPFUhyrFiMUKuOlUhdk1?	NHPKbFkzPjV4M{W2PC=>
THP89GFP	M17KZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NUfSbWNwTE2VT9Mg	MV;FR\|UxRTF7LkO0JOKyKDZwNEOgcm0>	MYeyOlU3OzV4OB?=
SK-NEP-1	M3q1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXfiV5ZlOC5yMfMAl\|ExNjBizszN	NIGwNnEzPCCq	NUTtdoZZTE2VT9Mg	MnzBTWM2OD15Nj6zOEBvVQ>?	MnnQNlYyPzZ{MUm=
G401	M2LwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHXu[2UxNjBz4pETNVAvOCEQvF2=	MlX5NlQhcA>?	M4\0WmROW00EoB?=	NHe5dodKSzVyPUG0N{4xOiCwTR?=	NHrKWnAzPjF5NkKxPS=>
SK-NEP-1	MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	M3;vNVUxKG6P	M3n3WVHjiJN2IHS=	M3Phb2ROW00EoB?=	MUDy[YR2[2W\|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	NHLoRnEzPjF5NkKxPS=>
G401	MYHD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MmSyOVAhdk1?	MnX3NgKBmzRiZB?=	MnraSG1UV8Li	MVvy[YR2[2W\|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MlLwNlYyPzZ{MUm=
SK-NEP-1	MWnBdI9xfG:\|aYOgRZN{[Xl?	MWG1NE8yODBibl2=	NYDrbpdiOjRiaB?=	MnjzSG1UV8Li	NV7zfJdMcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MmnoNlYyPzZ{MUm=
G401	NXTCdoVOSXCxcITvd4l{KEG\|c3H5	MlroOVAwOTByIH7N	MXOyOEBp	NELzRWVFVVORwrC=	MkHtbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M1;WdFI3OTd4MkG5
SK-NEP-1	M4noO2Z2dmO2aX;uJGF{e2G7	M{HkbVUxNzFyMDDuUS=>	M3XvblI1KGh?	M{KwdGROW00EoB?=	MUDzbI94eyC2aHWgbY5lfWO2aX;uJI9nKESQQTDmdoFodWWwdHH0bY9v	NWiwOI5pOjZzN{[yNVk>
G401	MYPGeY5kfGmxbjDBd5NigQ>?	M4K2blUxNzFyMDDuUS=>	NXPERlVvOjRiaB?=	NXOwbIpRTE2VT9Mg	NFO5SGx{cG:5czD0bIUhcW6mdXP0bY9vKG:oIFTORUBnemGpbXXueIF1cW:w	M3WwVlI3OTd4MkG5
SK-NEP-1	NFnWTo9HfW6ldHnvckBCe3OjeR?=	M4DTT\|UxNzFyMDDuUS=>	MkfzNlQhcA>?	NFP5PFlFVVORwrC=	NGTHOplqdmS3Y3XzJINmdGxiY4njcIUh\Gm\|b4Lk[ZLDqA>?	MoruNlYyPzZ{MUm=
G401	NIHhNZhHfW6ldHnvckBCe3OjeR?=	M2HDNlUxNzFyMDDuUS=>	NHvHPIUzPCCq	NHywcXpFVVORwrC=	Mn[1bY5lfWOnczDj[YxtKGO7Y3zlJIRqe2:{ZHXyxsA>	NX7hNWY{OjZzN{[yNVk>
RPMI 8226	MX;D[YxtKFO3co\peoFtKEG\|c3H5	NYXrXWp1Oi92L{[gcm0>	NH3SXms1QOLCiXi=		NVTKXIZicW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	NYfHepBlOjZyMECyPVI>
OPM2	NFXQTHZE\WyuIGP1dpZqfmGuIFHzd4F6	M2[0SlIwPC94IH7N	MYe0PQKBkWh?		MXLpcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	MVOyOlAxODJ7Mh?=
U266	NWD6[otzS2WubDDTeZJ3cX[jbDDBd5NigQ>?	MkfFNk81NzZibl2=	NEjN[Fc1QOLCiXi=		NVu1RplVcW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	NUS5doZ1OjZyMECyPVI>
H929	M17jO2NmdGxiU4Xyeol3[WxiQYPzZZk>	MmLENk81NzZibl2=	NHTLZVg1QOLCiXi=		MkTybY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>?	MWCyOlAxODJ7Mh?=
RPMI 8226	MYjBdI9xfG:\|aYOgRZN{[Xl?	M4XFXVTjiImwTR?=	M17IfVI1NzR6IHi=		NGLLUmxqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHnuJIEhfGmvZT3k[ZBmdmSnboSgcYFvdmW{	NVTCWINOOjZyMECyPVI>
HCC827	M{nmTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2GyflExKG6P	MUK0PEBp	M2fBWmROW09?	MXTlcohidmOnczDjbZNxdGG2aX6gd4Vve2m2aY\peJnDqA>?	M1Kxb\|I2QTR2NkG3
NCI-H23	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV\s[ZpuOTBibl2=	Mkn1OFghcA>?	NFm5Z3dFVVOR	MoPS[Y5p[W6lZYOgZ4l{eGyjdHnuJJNmdnOrdHn2bZR6yqB?	NH[zXXczPTl2NE[xOy=>
AML3	MV3GeY5kfGmxbjDBd5NigQ>?	NET1cI0xNTFizszN	NEC4NFQzPMLiaB?=		NWLCOZZncW6mdXPld{BFVkFiZoLh[41mdnSjdHnvcuKhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NFz2PVgzPTZzMkm0NS=>
ML-1	NHu3[XNHfW6ldHnvckBCe3OjeR?=	M4f1fVAuOSEQvF2=	NGLTVnMzPMLiaB?=		M4jHXolv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	Mkm5NlU3OTJ7NEG=
RPMI-8226vr10	MUnGeY5kfGmxbjDBd5NigQ>?	NEntR44xNTFizszN	MonKNlTDqGh?		MV7pcoR2[2W\|IFTORUBnemGpbXXueIF1cW:wwrDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	NXPGU2RbOjV4MUK5OFE>
ML-1	NXva[nV5TnWwY4Tpc44hSXO\|YYm=	MYWxJO69VQ>?	NF3iU28zPMLiaB?=		M3XSRolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhPC2ob3zk	MXOyOVYyOjl2MR?=
RPMI-8226vr10	NHfkfHJHfW6ldHnvckBCe3OjeR?=	NID6dIMyKM7:TR?=	M{nzSVI1yqCq		NFjWe\|ZqdmO{ZXHz[ZMh[2G\|cHHz[U0{KGGldHn2bZR6KDJwNT3mc4xl	NX;wZlB3OjV4MUK5OFE>
SK-N-BE (2)	NF24WpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NHq3UFYzPOLCiXi=		M4PoXmlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?=	NIPaT3EzPTNyOEmxOi=>
SK-N-BE (2), PAN MK	M1X3XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MYmyOQKBkWh?		NWKwR2xbUUN3ME2xNFQvOOLCidMx5qCKPy56IH7N	MnPJNlU{ODh7MU[=
SK-N-BE (2), MK PAN	NWLTW\|d3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M4LDWVI16oDLaB?=		M4\tU2lEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2=	NFf6[pAzPTNyOEmxOi=>
SK-N-AS	M1LIN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NH7j[48zPOLCiXi=		M2XERWlEPTB;M{euNgKBkcLz4pEJNk41KG6P	NFi0VJYzPTNyOEmxOi=>
SK-N-DZ	M1O0dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXuyOQKBkWh?		NFrYdlJKSzVyPUG3MlHjiIoEsfMAjVAvPCCwTR?=	M1HaeVI2OzB6OUG2
Caki-1	MnLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXuxNE8zPS93MDDuUS=>	NX76WmRlPDhiaB?=		M2e4O4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIILpeI9v[X[rch?=	M4fHO\|I2Ojd7MUmx
ACHN	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2HDTlExNzJ3L{WwJI5O	NXfNT\|l5PDhiaB?=		NF\BTnlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	NGK1d3gzPTJ5OUG5NS=>
769-P	M1S2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXGxNE8zPS93MDDuUS=>	MojEOFghcA>?		MlTVbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{	NEjxTZUzPTJ5OUG5NS=>
786-O	NFT6fotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHe0ZmcyOC9{NT:1NEBvVQ>?	M4X2dFQ5KGh?		NFjjN2tqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	M{\DT\|I2Ojd7MUmx
Caki-1	NY\2fZRGSXCxcITvd4l{KEG\|c3H5	M4nwWlUxKG6P	NXvUUJRiPDhiaB?=		NF\T[Y1qdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	M2fWTVI2Ojd7MUmx
ACHN	MVfBdI9xfG:\|aYOgRZN{[Xl?	MVW1NEBvVQ>?	M1vIVlQ5KGh?		MXnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>?	MVqyOVI4QTF7MR?=
769-P	MWfBdI9xfG:\|aYOgRZN{[Xl?	NYryZVUyPTBibl2=	MXy0PEBp		NE\tU\|FqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	M1nqdFI2Ojd7MUmx
786-O	NEDaZYVCeG:ydH;zbZMhSXO\|YYm=	M1LpZ\|UxKG6P	NHH0SZY1QCCq		M2TEW4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{	NVz0N5pqOjV{N{mxPVE>
Caki-1	NXjRO2V[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3znZVI2NzVyIH7N	MnvuOFghcA>?	MljISG1UVw>?	NIDhXZlqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni	NGDYdmIzPTF5NkO1OC=>
ACHN	M4DYNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUiyZ5RkOjVxNUCgcm0>	NGezdmo1QCCq	MkP4SG1UVw>?	MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk	MW[yOVE4PjN3NB?=
769-P	NHjDZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX21U3c2OjVxNUCgcm0>	NHSze\|c1QCCq	MYjEUXNQ	MULpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldkB{gW6ncnfpd5Rq[2GubImge4l1cCCkb4L0[ZpwdWmk	NHvsZoczPTF5NkO1OC=>
Caki-1	MknrR49td267IF\vdo1ifGmxbjDBd5NigQ>?	MV:1NEBvVQ>?	NWHRWGdNPy1zNDDk	MoTLSG1UVw>?	MlLnd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	NFPkUmIzPTF5NkO1OC=>
ACHN	MmHQR49td267IF\vdo1ifGmxbjDBd5NigQ>?	M1S1d\|UxKG6P	MnnMO{0yPCCm	MlrOSG1UVw>?	M4jiXpN2eHC{ZYPz[YQh[2:ub375JIZwem2jdHnvckB{cWewaX\pZ4FvfGy7IHPvcYJqdmWmIIfpeIghf2m2aDDic5J1\XqxbXniJOKh	NWO0UnFqOjVzN{[zOVQ>
769-P	M3;mOmNwdG:weTDGc5Ju[XSrb36gRZN{[Xl?	NIPxcIs2OCCwTR?=	M3frdVcuOTRiZB?=	MX3EUXNQ	Mn3Pd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	MUOyOVE4PjN3NB?=
Caki-1	NXnjOWRNSXCxcITvd4l{KEG\|c3H5	M2jWdFUxKG6P	MmC2OFghcA>?	NWDRTnBZTE2VTx?=	NVnIUm1wcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NFPGTGIzPTF5NkO1OC=>
ACHN	NH;5XVhCeG:ydH;zbZMhSXO\|YYm=	MoXOOVAhdk1?	MV:0PEBp	M2jrTWROW09?	NULSdVgzcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NHvHb4YzPTF5NkO1OC=>
769-P	NF7JXopCeG:ydH;zbZMhSXO\|YYm=	MlvaOVAhdk1?	MX20PEBp	MlLvSG1UVw>?	NXH3fYJVcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M3jUdlI2OTd4M{W0
MDA-MB-231	MYXNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	MkDVNVDDqG6P	NYHTfpVMO8LiZB?=	MmH6SG1UVw>?	Mni2ZYx1\XK\|IHPlcIwhdW:{cHjvcI9ogcLi	NIfsd2kzPDhzMES5Oy=>
BT-549	MWDNc5JxcG:ub3fpZ4FtKEO{eYP0ZYwhXmmxbHX0JEhEXiliQYPzZZk>	MoLsNVDDqG6P	MmLPN:Kh\A>?	M1riXWROW09?	MUPhcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	NFnTe5IzPDhzMES5Oy=>
MCF-7	MmSwUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	NH3XeosyOMLibl2=	M4LPNlPDqGR?	M4fo[2ROW09?	M3TFbIFtfGW{czDj[YxtKG2xcoDoc4xw\3oEoB?=	MV[yOFgyODR7Nx?=
MCF-7	MYLGeY5kfGmxbjDBd5NigQ>?	M4TPZlUuPTBibl2=	NILKemEzPCCq	NILFXXhFVVOR	M13XdJJm\HWlZXSgeIhmKGyndnXsJI9nKGW6cILld5Nqd25ib3[gSXLPuSxiUGKgZY5lKE[xeFGxxsA>	MVKyOFM3PjRyNx?=
CTS	M{jZZWFxd3C2b4Ppd{BCe3OjeR?=	MWCw5qCUPDBibl5CpC=>	MoHoOFghcA>?		NEXDOolqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MVOyOFI1PDR{OR?=
OCI-AML3	M4Hkb2Fxd3C2b4Ppd{BCe3OjeR?=	MmjnNQKBmzRyIH7NxsA>	MkH0OFghcA>?		NHS3[GpqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NFXHbY8zPDJ2NESyPS=>
U937	NXmwN256SXCxcITvd4l{KEG\|c3H5	NFnlRWox6oDVNECgcm3DqA>?	MoTNOFghcA>?		MlGxbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M2XyelI1OjR2NEK5
PC3	NXTRboU2SXCxcITvd4l{KEG\|c3H5	NI\YSYQxNTFyMDDuUS=>	NEf2[XozPC92ODDo		NXnmUFBvcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	M{m5XlI1OTZ\|MkOw
PC3-AR	NWHoVJhwSXCxcITvd4l{KEG\|c3H5	NYjkSGdmOC1zMECgcm0>	NWfuNo42OjRxNEigbC=>		MmHXbY5lfWOnczDhdI9xfG:\|aYOgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S2mZYDlcoRmdnRibXHucoVz	NFqyPVAzPDF4M{KzNC=>
PC3	M{jOPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGTBeWExNTFyMDDuUS=>	NFHmT2UzPC92ODDo		MYjpcoR2[2W\|IHHjZ5VufWyjdHnvckBw\iC\|dXLHNUBxd3C3bHH0bY9v	M1nMXlI1OTZ\|MkOw
PC3-AR	NXPsdWp4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHPTnRzOC1zMECgcm0>	M3fWPVI1NzR6IHi=		Ml\nbY5lfWOnczDj[YxtKGO7Y3zlJIFzemW\|dDDpckB1cGViR{LNJJBp[XOn	NG[0UYczPDF4M{KzNC=>
PC3	NUHkVVI2TnWwY4Tpc44hSXO\|YYm=	NYHDXmNkOC1zMECgcm0>	M1vqXFI1KGh?		NYPBfJQ3e3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4>	NUn5NWtKOjRzNkOyN\|A>
PC3-AR	NYTETG5HTnWwY4Tpc44hSXO\|YYm=	NGPtXFcxNTFyMDDuUS=>	MYWyOEBp		MU\zeZBxemW\|c3XzJIV5eHKnc4Ppc44hd2ZiYXP0bZZifGWmIFHUUUwhSWu2IHHu[EBGemtzL{KgdJJwfGWrbh?=	NVS0fFhlOjRzNkOyN\|A>
OS-RC-2	NWnBZmFCS2WubDDWbYFjcWyrdImgRZN{[Xl?	NF7MUYsxNTFyMECgcm0>	MkGxNlQwPDhxN{KgbC=>	NFy3N4pFVVOR	MnHx[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MoXwNlQyPDR5M{e=
OS-RC-2	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;xdFUxKG6P	MYC0PEBp	MXvEUXNQ	MYDpcoR2[2W\|IFeyM20h[XK{ZYP0	M3HvdFI1OTR2N{O3
OS-RC-2	NInlOHFCeG:ydH;zbZMhSXO\|YYm=	NVLpOmpoPTBibl2=	NIS3TGQ1QCCq	M1mxemROW09?	Mnq2bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NVf6UVhxOjRzNES3N\|c>
SK-N-AS	M2rvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NX\XdW9SOOLCk{iwJI5O	MXW0PEBp		MlHKTWM2OD1{Nz60JI5O	M3PYR\|I1ODl6N{m5
SK-N-DZ	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYjwblVkOOLCk{iwJI5O	NYP5NHhRPDhiaB?=		Mm[4TWM2OD1{MT65JI5O	MVyyOFA6QDd7OR?=
SK-N-SH	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHe3UFEx6oDVOECgcm0>	MVi0PEBp		M4j1VWlEPTB;N{KuN{BvVQ>?	MUGyOFA6QDd7OR?=
SK-N-BE	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYGw5qCUQDBibl2=	NETUVVE1QCCq		NUTGSIJPUUN3ME23OU41KG6P	MYiyOFA6QDd7OR?=
SK-N-AS	MlvERZBweHSxc3nzJGF{e2G7	M4fk[lDjiJN6MDDuUS=>	NW\5cJRxPDhiaB?=		NH7aTmVxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	NF[5em8zPDB7OEe5PS=>
SK-N-DZ	MVXBdI9xfG:\|aYOgRZN{[Xl?	MnXRNQKBmzhyIH7N	M1PaeFQ5KGh?		NHqxeWZxd3SnboTsfUBqdmS3Y3XkJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG[jc3jpc44>	MUKyOFA6QDd7OR?=
SK-N-SH	M37YVGFxd3C2b4Ppd{BCe3OjeR?=	MkfoNQKBmzRyIH7N	NFXzOWE1QCCq		MmX3dI91\W62bImgbY5lfWOnZDDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBn[XOqaX;u	MkG3NlQxQTh5OUm=
SK-N-BE	NH7KUJlCeG:ydH;zbZMhSXO\|YYm=	M3HHU\|DjiJN2MDDuUS=>	MlTROFghcA>?		M1K0fJBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	NFrTV3UzPDB7OEe5PS=>
SK-N-AS	NHfIfoVHfW6ldHnvckBCe3OjeR?=	NGjvNHox6oDVOECgcm0>	NHu5dZk1QCCq		MmXBbY5lfWOnczDhJIRwe2VvZHXw[Y5l\W62IHPs[YF3[WenIH;mJINie3Cjc3WgN{BidmRiUFHSVC=>	NYf3ZnIyOjRyOUi3PVk>
SK-N-DZ	M2DqbGZ2dmO2aX;uJGF{e2G7	NEexSnIx6oDVOECgcm0>	MUm0PEBp		M2PlT4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	MkHuNlQxQTh5OUm=
SK-N-SH	NVnwSndzTnWwY4Tpc44hSXO\|YYm=	MWqw5qCUPDBibl2=	NHXoU241QCCq		M4rMXolv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	MYmyOFA6QDd7OR?=
SK-N-BE	M2DRTWZ2dmO2aX;uJGF{e2G7	NFHlfWwx6oDVNECgcm0>	MkixOFghcA>?		NUfz[G1{cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	M3O4bFI1ODl6N{m5
HCC-LM3	NXvhRm93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{CwNVEuOTByMDDuUS=>	MYGyOE81QC95MjDo	MmLWSG1UVw>?	NUX3ZndZcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MYqyOFA6Ozl3Nh?=
HepG2	M{myNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4PMbFEuOTByMDDuUS=>	MljyNlQwPDhxN{KgbC=>	NH[2fW1FVVOR	NV\w[2tQcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M{jSR\|I1ODl\|OUW2
SMMC-7721	MlvkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV7JcYsyOS1zMECwJI5O	MoGzNlQwPDhxN{KgbC=>	MoLwSG1UVw>?	MX3pcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	MVeyOFA6Ozl3Nh?=
HCC-LM3	Mn3lRZBweHSxc3nzJGF{e2G7	NIK1VWo2OCCwTR?=	M1WzZ\|Q5KGh?	M3\we2ROW09?	NH3hW4pqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhOyxiODDhcoQhQQ>?	MXKyOFA6Ozl3Nh?=
HepG2	MXrBdI9xfG:\|aYOgRZN{[Xl?	MYS1NEBvVQ>?	MWe0PEBp	M3ruZmROW09?	MYXpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KHOrZ37p[olk[W62bImgbY4h[SClYYPwZZNmNWSncHXu[IVvfCCvYX7u[ZIh[nliY3zlZZZi\2Vib3[gZ4F{eGG\|ZYOgN{whQCCjbnSgPS=>	NHi0Z\|YzPDB7M{m1Oi=>
SMMC-7721	NW\LZYxCSXCxcITvd4l{KEG\|c3H5	Ml7sOVAhdk1?	M3Lp[VQ5KGh?	NHKzeohFVVOR	M2TRe4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3nncolncWOjboTsfUBqdiCjIHPhd5Bie2VvZHXw[Y5l\W62IH3hco5meiCkeTDjcIVifmGpZTDv[kBk[XOyYYPld{A{NCB6IHHu[EA6	M3XsVlI1ODl\|OUW2
HCC-LM3	MoizSpVv[3Srb36gRZN{[Xl?	NGDTOHo2OC9zMECgcm0>	MUmyOEBp	MWnEUXNQ	NILST5dl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR\|IHHu[EBxNUGtdNMg	NH3wZXMzPDB7M{m1Oi=>
HepG2	NGqwVFhHfW6ldHnvckBCe3OjeR?=	MXS1NE8yODBibl2=	NV\JNpI4OjRiaB?=	MkHUSG1UVw>?	NEm5XZNl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR\|IHHu[EBxNUGtdNMg	MXGyOFA6Ozl3Nh?=
SMMC-7721	NWCyTVV3TnWwY4Tpc44hSXO\|YYm=	MU[1NE8yODBibl2=	MnLnNlQhcA>?	M1vod2ROW09?	NHnZR3dl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR\|IHHu[EBxNUGtdNMg	MWSyOFA6Ozl3Nh?=
HCC-LM3	MnTNSpVv[3Srb36gRZN{[Xl?	NX;JVoJXPTBxMUCwJI5O	NHGwRWozPCCq	NV\CbnFDTE2VTx?=	Mnf0[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>?	MlqwNlQxQTN7NU[=
HepG2	MkLBSpVv[3Srb36gRZN{[Xl?	M3HIS\|UxNzFyMDDuUS=>	M1rKNlI1KGh?	M{LhVWROW09?	NVHuPJpi\G:5boLl[5Vt[XSnczDCZ4wugExiZYjwdoV{e2mxbh?=	MWeyOFA6Ozl3Nh?=
SMMC-7721	MUHGeY5kfGmxbjDBd5NigQ>?	NF3scG02OC9zMECgcm0>	M1TZSFI1KGh?	MWXEUXNQ	NHnOVHFld3ewcnXneYxifGW\|IFLjcE15VCCneIDy[ZN{cW:w	NG\0c4IzPDB7M{m1Oi=>
FaDu	M3;BNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV2xNFDjiIWwTR?=	NV:4SFhSQC9zMD:xNkBp		NX;CPWs1\Gm\|cHzhfYVlKGFic3nncolncWOjboSgZY5lKHC{b3zvcodm\CCJMj;NJIFzemW\|dDDheEA5KGGwZDCxNwKBjWhicH;zeEBz\WynYYPl	NI\USZMzPDB{NkS4Ni=>
FaDu	MlLiSpVv[3Srb36gRZN{[Xl?	MWSxNFDjiIWwTR?=	MlywNk81NzhxMUKgbC=>		M2\xdolv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w	NEjGdYUzPDB{NkS4Ni=>
PC-3	NXrMRVR1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorENE0yOCEQvF2=	MojWNlQwPDhxN{KgbC=>		NU[zcGxqcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MVGyN\|k6OTJzNh?=
LNCaP	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV63cHNmOC13IN88US=>	MW[yOE81QC95MjDo		MkXtbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	M1XXNlI{QTlzMkG2
RWPE-1	MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmnmNE0zOCEQvF2=	MXmyOE81QC95MjDo		NY\LfXZHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MWKyN\|k6OTJzNh?=
Capan-1	NVG1WI1QTnWwY4Tpc44hSXO\|YYm=	Ml7mNlUwPTBxMUCwJI5O	NGPMTIc5NzJ2L{S4JIg>	NF7QZ\|VFVVOR	NYXEWolt\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=>	MmCxNlM6OjJ6OE[=
L3.6pl	M4m2WWZ2dmO2aX;uJGF{e2G7	MXGyOU82OC9zMECgcm0>	M2m5V\|gwOjRxNEigbC=>	NIfP[3dFVVOR	Moq4[I94dnKnZ4XsZZRm\CCUb36gcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO\|aX;uJIFv\CCmb4fud5Rz\WGvIIPp[45idGmwZx?=	Mn3nNlM6OjJ6OE[=
CFPAC-1	NV\ESIVrTnWwY4Tpc44hSXO\|YYm=	M2fxblI2NzVyL{GwNEBvVQ>?	NIT5cVI5NzJ2L{S4JIg>	M3nC[mROW09?	NXnpSYU3\G:5boLl[5Vt[XSnZDDSc44hdVKQQTDhcoQheHKxdHXpckBmgHC{ZYPzbY9vKGGwZDDkc5dve3S{ZXHtJJNq\26jbHnu[y=>	MoX1NlM6OjJ6OE[=
Capan-1	M{LFeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NED5RpUzPS93MD:xNFAhdk1?	MlXkOFghcA>?	MV7EUXNQ	MnT3doVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NFPV[oEzOzl{Mki4Oi=>
L3.6pl	NHfVXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIj6PJgzPS93MD:xNFAhdk1?	MYC0PEBp	MXjEUXNQ	MkHRdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MlG5NlM6OjJ6OE[=
CFPAC-1	M3rHSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVXWTINiOjVxNUCvNVAxKG6P	NW[xWZpYPDhiaB?=	NXXzNmdqTE2VTx?=	MnvNdoVlfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	Mn7vNlM6OjJ6OE[=
Capan-1	NXXBU5RuSXCxcITvd4l{KEG\|c3H5	NUXoUnB5OjVxNUCvNVAxKG6P	NXrCWXNOPDhiaB?=	NXywW3FwTE2VTx?=	M3q5T4lv\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MVKyN\|kzOjh6Nh?=
L3.6pl	MX;BdI9xfG:\|aYOgRZN{[Xl?	NHLtbYYzPS93MD:xNFAhdk1?	MmHEOFghcA>?	NWC2ZpVMTE2VTx?=	MmLVbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	M17Re\|I{QTJ{OEi2
CFPAC-1	M4e5[WFxd3C2b4Ppd{BCe3OjeR?=	NWLmcZZVOjVxNUCvNVAxKG6P	NIjHU481QCCq	NVXzRll3TE2VTx?=	NV3PNlBicW6mdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	M2jkZVI{QTJ{OEi2
HN22	MnXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1rtbFAuOjBibl2=	MYiyOE81QCCq	NE[1Z2FFVVOR	NWLrcoZmcW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>?	NXvse4gzOjN6N{eyN\|U>
HSC4	M1\4Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXuwMVIxKG6P	NHvVN3kzPC92ODDo	M2XjPGROW09?	MXnpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy	NVnwboZMOjN6N{eyN\|U>
HN22	NYj3OVZySXCxcITvd4l{KEG\|c3H5	MVOwMVIxKG6P	MXe0PEBp	M2\TdmROW09?	NVfPSmR[cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NFrwU4YzOzh5N{KzOS=>
HSC4	Ml7oRZBweHSxc3nzJGF{e2G7	M1XPeFAuOjBibl2=	NHfhSI41QCCq	MlvNSG1UVw>?	NX:2N5c4cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NE\Wc4ozOzh5N{KzOS=>
HN22	Mn3xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\JR2oxNTJyIH7N	NYPV[XZDPDhiaB?=	NH7KTlVFVVOR	M{X1O4lv\HWlZYOgS\|EheGijc3WgZ4VtdCCleXPs[UBienKnc4VCpC=>	MoLkNlM5Pzd{M{W=
HSC4	NH\1SJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnSR2JCOC1{MDDuUS=>	Moq3OFghcA>?	Mn2xSG1UVw>?	NFjDOWpqdmS3Y3XzJGcyKHCqYYPlJINmdGxiY4njcIUh[XK{ZYP0xsA>	Ml7PNlM5Pzd{M{W=
HN22	MXfGeY5kfGmxbjDBd5NigQ>?	MUCwMVIxKG6P	NWjSOoV3PDhiaB?=	NHTDSVhFVVOR	MnTMd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg	MmLoNlM5Pzd{M{W=
HSC4	M2jnSmZ2dmO2aX;uJGF{e2G7	MoTQNE0zOCCwTR?=	M{TiSVQ5KGh?	NVH5O4xsTE2VTx?=	Ml;yd5VxeHKnc4Pld{BUeDFiZYjwdoV{e2mxbtMg	NX33eZUyOjN6N{eyN\|U>
Cal62	NUntPZFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTN\|INMxJFQhdk1?	MnPyNlM5OjRyNkS=
Hth7	NFTOUlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHHCfWRKSzVyPUG1JOKyKDJibl2=	MY[yN\|gzPDB4NB?=
Hth83	NFzUbZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTN2INMxJFUhdk1?	MmnjNlM5OjRyNkS=
C643	NYP3ToJbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWLJR\|UxRTdzINMxJFExKG6P	MXSyN\|gzPDB4NB?=
SW1736	NF\JOJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4\RNmlEPTB;M{WgxtEhQCCwTR?=	MYWyN\|gzPDB4NB?=
T241	NEDJOXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnRTWM2OD14NTFCtUA4KG6P	M4DadFI{QDJ2ME[0
T351	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTVyINMxJFExKG6P	M3PKd\|I{QDJ2ME[0
BHP2-7	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWnJR\|UxRTN5INMxJFYhdk1?	MkT0NlM5OjRyNkS=
T238	NXvxWXlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{TCVGlEPTB;MTy1NFAhyrFiMkCwJI5O	NF7YRWozOzh{NEC2OC=>
HCT8	M{XwZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M3HaeVczKGh?	NGDYR5dFVVOR	MnvtTWM2OD1zMj655qCKyrIkgJmxMlkhdk1?	MYmyN\|I6QTN6OB?=
H630	NGfhXXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVrTSJhXPzJiaB?=	M3n4b2ROW09?	MX\JR\|UxRTF{LkVihKnDueLCiUOuNUBvVQ>?	M4DJ[VI{Ojl7M{i4
cH630 5-FU-res	NULxbnZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFH6T3U4OiCq	Ml3TSG1UVw>?	NE\zWFlKSzVyPUG1MlXjiIoEsfMAjVEvOiCwTR?=	NFr4dWkzOzJ7OUO4PC=>
HCT116	M1nJTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MoPHO\|IhcA>?	NYPtUmlHTE2VTx?=	MUPJR\|UxRTFyLkhihKnDueLCiUKuNkBvVQ>?	M3HQTFI{Ojl7M{i4
HCT116 p53−/−	M{Thcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXW3NkBp	MWHEUXNQ	MWnJR\|UxRThwNvMAjeKy6oDLMT63JI5O	M2rmXVI{Ojl7M{i4
dHCT116 p21−/−	NEf3PWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NYm3VoZCPzJiaB?=	MUHEUXNQ	M1fxXmlEPTB;NT655qCKyrIkgJmxMlMhdk1?	MlnRNlMzQTl\|OEi=
HT29	M1Sw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NVv6c2VVPzJiaB?=	NW\qSXRJTE2VTx?=	M3voRmlEPTB;MU[uN-KBkcLz4pEJNk4{KG6P	NYLkT2NbOjN{OUmzPFg>
LoVo	NXK5dHhjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		Mlv1O\|IhcA>?	NV\6WGprTE2VTx?=	Mk\QTWM2OD13LkJihKnDueLCiUCuOkBvVQ>?	MXqyN\|I6QTN6OB?=
RKO	M2DWUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIKydm04OiCq	NYPTOnBqTE2VTx?=	NYfsWFd5UUN3ME23MlnjiIoEsfMAjVIvOiCwTR?=	MoW0NlMzQTl\|OEi=
SW480	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MUK3NkBp	M3fqWmROW09?	MofnTWM2OD1zNz615qCKyrIkgJmwMlghdk1?	NVm5eHFTOjN{OUmzPFg>
eSW620	NFXDZmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2DHTFczKGh?	MmfSSG1UVw>?	M3PKO2lEPTB;OT6x5qCKyrIkgJmyMlEhdk1?	MV2yN\|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

In vivo

In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. ^[2]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
Concentrations: 50 nM
Incubation Time: 48 hours
Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 10⁴ cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
(Only for Reference)

Animal Research:^[2]

- Collapse

Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (10⁷ cells) or A549 (5 × 10⁶ cells), H69 (2.5 × 10⁶ cells), BK-T (6.5 × 10⁶), H526 (10 × 10⁶), and RG1 (10 × 10⁶) cells
Dosages: 10 mg/kg, 20 mg/kg
Administration: Administered via i.p. injection
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+48% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Panobinostat (LBH589) SDF

Molecular Weight	349.43
Formula	C₂₁H₂₃N₃O₂
CAS No.	404950-80-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	NVP-LBH589
Smiles	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=C([NH]1)C=CC=C3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04341311	Not yet recruiting	Drug: Marizomib\|Drug: Panobinostat	Diffuse Intrinsic Pontine Glioma\|Pediatric Brainstem Glioma\|Pediatric Brainstem Gliosarcoma Recurrent\|Pediatric Cancer\|Pediatric Brain Tumor\|Diffuse Glioma	Dana-Farber Cancer Institute\|Celgene\|Secura Bio	May 2020	Phase 1
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT04326764	Recruiting	Drug: Panobinostat	Acute Myeloid Leukaemia (AML)\|Myelodysplastic Syndromes (MDS)	Goethe University\|Jan J. Cornelissen (HOVON-SAKK)\|Sebastian Giebel (PALG)	July 24 2018	Phase 3
NCT03515915	Unknown status	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo mice study?
Answer:
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay. Vorinostat abrogates productive HPV-18 DNA amplification.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively. Romidepsin (FK228/depsipeptide) controls growth and induces apoptosis in neuroblastoma tumor cells.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold). Tubastatin A promotes autophagy and increases apoptosis.
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Mocetinostat (MGCD0103) induces apoptosis and autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Panobinostat (LBH589)